Fortuna Mining Corp. Common Shares vs State Street SPDR S&P Biotech ETF — how do they compare? Fortuna Mining Corp. Common Shares trades at $10.87 (market cap $3.01B), while State Street SPDR S&P Biotech ETF trades at $149.99 (market cap $10.08B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 3.3× Fortuna Mining Corp. Common Shares's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Fortuna Mining Corp. Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortuna Mining Corp. Common Shares for 0 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| FSM | XBI | |
|---|---|---|
Market Cap | $3.01B | $10.08B |
Volume | 10,925,733 | 9,534,635 |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $13.66 | $169.55 |
52-Week Low | $7.84 | $104.99 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $2.63B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $150.23, down 0.44% on the day, with bearish technical signals dominating. The ETF faces resistance near $152-154 while finding support at $147-149 levels. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech sector optimism from M&A activity and cancer vaccine breakthroughs. The fund's 0.35% expense ratio compares unfavorably to broader healthcare ETFs but offers targeted biotech exposure.
Outlook remains mixed with technical weakness offset by sector catalysts. The biotech focus provides growth potential but carries higher volatility than diversified healthcare alternatives. Key risks include sector-specific regulatory pressures and the fund's expense structure, while opportunities exist from ongoing pharmaceutical innovation and capital market improvements.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Fortuna Mining is a Canadian precious-metals mining company with operations in Latin America and West Africa. It produces gold and silver and conducts exploration activities in several countries.
Read more on FSM →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →